vs
Side-by-side financial comparison of UGI CORP (UGI) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $2.1B, roughly 1.2× UGI CORP). Zoetis runs the higher net margin — 25.3% vs 14.4%, a 10.9% gap on every dollar of revenue. On growth, UGI CORP posted the faster year-over-year revenue change (3.9% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $-155.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -7.5%).
UGI Corporation is a natural gas and electric power distribution company headquartered in King of Prussia, Pennsylvania, with extensive operations in the United States and Europe.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
UGI vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.1B | $2.4B |
| Net Profit | $297.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 22.0% | 31.9% |
| Net Margin | 14.4% | 25.3% |
| Revenue YoY | 3.9% | 3.0% |
| Net Profit YoY | -20.8% | 3.8% |
| EPS (diluted) | $1.34 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.1B | $2.4B | ||
| Q3 25 | $1.2B | $2.4B | ||
| Q2 25 | $1.4B | $2.5B | ||
| Q1 25 | $2.6B | $2.2B | ||
| Q4 24 | $2.0B | $2.3B | ||
| Q3 24 | $1.2B | $2.4B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $2.4B | $2.2B |
| Q4 25 | $297.0M | $603.0M | ||
| Q3 25 | $-13.0M | $721.0M | ||
| Q2 25 | $-163.0M | $718.0M | ||
| Q1 25 | $479.0M | $631.0M | ||
| Q4 24 | $375.0M | $581.0M | ||
| Q3 24 | $-273.0M | $682.0M | ||
| Q2 24 | $-48.0M | $624.0M | ||
| Q1 24 | $496.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 22.0% | 31.9% | ||
| Q3 25 | 1.1% | 37.0% | ||
| Q2 25 | -6.8% | 36.7% | ||
| Q1 25 | 26.6% | 36.5% | ||
| Q4 24 | 24.5% | 31.6% | ||
| Q3 24 | -20.4% | 36.6% | ||
| Q2 24 | 5.0% | 33.0% | ||
| Q1 24 | 29.7% | 34.1% |
| Q4 25 | 14.4% | 25.3% | ||
| Q3 25 | -1.1% | 30.0% | ||
| Q2 25 | -12.0% | 29.2% | ||
| Q1 25 | 18.2% | 28.4% | ||
| Q4 24 | 18.9% | 25.1% | ||
| Q3 24 | -22.6% | 28.6% | ||
| Q2 24 | -3.6% | 26.4% | ||
| Q1 24 | 20.6% | 27.4% |
| Q4 25 | $1.34 | $1.37 | ||
| Q3 25 | $-0.08 | $1.63 | ||
| Q2 25 | $-0.76 | $1.61 | ||
| Q1 25 | $2.19 | $1.41 | ||
| Q4 24 | $1.74 | $1.29 | ||
| Q3 24 | $-1.26 | $1.50 | ||
| Q2 24 | $-0.23 | $1.37 | ||
| Q1 24 | $2.30 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $251.0M | — |
| Total DebtLower is stronger | $6.0B | — |
| Stockholders' EquityBook value | $5.0B | $3.3B |
| Total Assets | $15.8B | $15.5B |
| Debt / EquityLower = less leverage | 1.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $251.0M | — | ||
| Q3 25 | $335.0M | $2.1B | ||
| Q2 25 | $350.0M | $1.4B | ||
| Q1 25 | $426.0M | $1.7B | ||
| Q4 24 | $240.0M | $2.0B | ||
| Q3 24 | $213.0M | $1.7B | ||
| Q2 24 | $183.0M | $1.6B | ||
| Q1 24 | $263.0M | $2.0B |
| Q4 25 | $6.0B | — | ||
| Q3 25 | $6.5B | — | ||
| Q2 25 | $5.7B | — | ||
| Q1 25 | $6.6B | — | ||
| Q4 24 | $6.6B | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.7B | — |
| Q4 25 | $5.0B | $3.3B | ||
| Q3 25 | $4.8B | $5.4B | ||
| Q2 25 | $4.9B | $5.0B | ||
| Q1 25 | $5.0B | $4.7B | ||
| Q4 24 | $4.6B | $4.8B | ||
| Q3 24 | $4.3B | $5.2B | ||
| Q2 24 | $4.7B | $5.0B | ||
| Q1 24 | $4.8B | $5.1B |
| Q4 25 | $15.8B | $15.5B | ||
| Q3 25 | $15.5B | $15.2B | ||
| Q2 25 | $15.4B | $14.5B | ||
| Q1 25 | $15.7B | $14.1B | ||
| Q4 24 | $15.4B | $14.2B | ||
| Q3 24 | $15.1B | $14.4B | ||
| Q2 24 | $15.1B | $14.2B | ||
| Q1 24 | $15.6B | $14.3B |
| Q4 25 | 1.19× | — | ||
| Q3 25 | 1.37× | — | ||
| Q2 25 | 1.17× | — | ||
| Q1 25 | 1.32× | — | ||
| Q4 24 | 1.44× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.34× | — | ||
| Q1 24 | 1.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.0M | $893.0M |
| Free Cash FlowOCF − Capex | $-155.0M | $732.0M |
| FCF MarginFCF / Revenue | -7.5% | 30.7% |
| Capex IntensityCapex / Revenue | 10.7% | 6.7% |
| Cash ConversionOCF / Net Profit | 0.22× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $282.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.0M | $893.0M | ||
| Q3 25 | $90.0M | $938.0M | ||
| Q2 25 | $289.0M | $486.0M | ||
| Q1 25 | $684.0M | $587.0M | ||
| Q4 24 | $164.0M | $905.0M | ||
| Q3 24 | $151.0M | $951.0M | ||
| Q2 24 | $390.0M | $502.0M | ||
| Q1 24 | $522.0M | $595.0M |
| Q4 25 | $-155.0M | $732.0M | ||
| Q3 25 | $-168.0M | $805.0M | ||
| Q2 25 | $67.0M | $308.0M | ||
| Q1 25 | $538.0M | $438.0M | ||
| Q4 24 | $-47.0M | $689.0M | ||
| Q3 24 | $-115.0M | $784.0M | ||
| Q2 24 | $185.0M | $370.0M | ||
| Q1 24 | $353.0M | $455.0M |
| Q4 25 | -7.5% | 30.7% | ||
| Q3 25 | -14.4% | 33.5% | ||
| Q2 25 | 4.9% | 12.5% | ||
| Q1 25 | 20.4% | 19.7% | ||
| Q4 24 | -2.4% | 29.7% | ||
| Q3 24 | -9.5% | 32.8% | ||
| Q2 24 | 13.7% | 15.7% | ||
| Q1 24 | 14.6% | 20.8% |
| Q4 25 | 10.7% | 6.7% | ||
| Q3 25 | 22.1% | 5.5% | ||
| Q2 25 | 16.3% | 7.2% | ||
| Q1 25 | 5.5% | 6.7% | ||
| Q4 24 | 10.6% | 9.3% | ||
| Q3 24 | 22.0% | 7.0% | ||
| Q2 24 | 15.2% | 5.6% | ||
| Q1 24 | 7.0% | 6.4% |
| Q4 25 | 0.22× | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | 1.43× | 0.93× | ||
| Q4 24 | 0.44× | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | 1.05× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
UGI
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
